5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial - Gianni, L; Pienkowski, T; Im, Y H (Lancet Oncol, 2016)